Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial have?
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial has 3,664 citations in the OpenAlex counts ScholarIQ stores.
When was Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial published?
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial has 2020 year in the ScholarIQ index.
What is the open-access status of Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial?
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial has bronze oa status in the ScholarIQ index.
What is the DOI of Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial?
The DOI for Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial is on the source record.
What is the PMID of Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial?
The PMID for Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial is on the source record.
What is the OpenAlex record for Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial?
The OpenAlex for Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial is on the source record.